Direct Flow Medical, Inc. Transcatheter Aortic Valve System Continues to Demonstrate Excellent Outcomes at Six Months in DISCOVER CE Mark Trial

Published: Oct 29, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN FRANCISCO--(BUSINESS WIRE)--Direct Flow MedicalĀ®, Inc., a transcatheter heart valve innovator focused on improving patient outcomes, today announced six-month data from the fully-enrolled DISCOVER CE Mark Trial that continue to affirm the excellent outcomes and strong safety profile of the Direct Flow MedicalĀ® Transcatheter Aortic Valve System. The data, which were presented on Monday at the Transcatheter Cardiovascular Therapeutics (TCT) conference, demonstrated sustained results at six months, with 96 percent freedom from all-cause mortality and no incidence of moderate or severe post-procedural aortic regurgitation. Principal Investigator Joachim Schofer, M.D., from the Medical Care Center, Hamburg, Germany, presented the results.

Help employers find you! Check out all the jobs and post your resume.

Back to news